您还需要查看 Eliquis 的利润贡献

GREED WATCH: Bristol Myers Squibb Brought In More Than $45 Billion In 2023

https://www.protectourcare.org/greed-watch-bristol-myers-squibb-brought-in-more-than-45-billion-in-2023/

2019年FDA已批准Eliquis仿制药。 BMY使用各种策略将其专利延长至2026年。为什么？ 药品贡献了其2/3的利润。 Eliquis是Medicare处方中的NO.1药物，受益人数最多的会员 (3.5 million)。虽然Medicare花费最多的不是Eliquis，而是两种癌症药物，每种药物只惠及不到3万名会员。

Eiquis is at about $600 a month.  Many Medicare Advantage plans cover it with only $5 co-pay  but pay the full cost of the drug. 

2024 Medicar Plan D allowance is 5030.  Once over that you enter the donut hole (coverage gap)

At $600 a month, a patient even ONLY needs Eliquis (hardly likely),  would go into donut hole by August. 

8x600 = 4800. 

一旦进入 Donut Hole，患者将承担25%的药品费用加上配药费（由配药的药房收取）。

Basically BMY is a 吸血者.  It is about time to do something to stop the sleazy tactics big pharma used, i.e. using loophole to extend patent.

所有跟帖： 

• 这个听上去就像是FDA的问题呀 -自了汉- ♂ (45 bytes) () 04/30/2024 postreply 08:34:18

• No. Patent can be legally extended thru many ways. -goingplaces- ♀ (102 bytes) () 04/30/2024 postreply 10:48:25